These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35635046)

  • 1. Successful Treatment of Tenofovir Alafenamide-Induced Lactic Acidosis: A Case Report.
    Arnouk S; Whitsett M; Papadopoulos J; Stewart Lewis Z; Dagher NN; Feldman DM; Park JS
    J Pharm Pract; 2023 Oct; 36(5):1260-1263. PubMed ID: 35635046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
    Ying Y; Hu YK; Jin JL; Zhang JM; Zhang WH; Huang YX
    BMC Gastroenterol; 2018 Apr; 18(1):45. PubMed ID: 29625557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
    Alsunaid SR; Ashraf H; Soubani AO
    Transpl Infect Dis; 2018 Oct; 20(5):e12960. PubMed ID: 29975806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal lactic acidosis in hepatitis B virus-associated decompensated cirrhosis treated with tenofovir: A case report.
    Jung TY; Jun DW; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS
    Medicine (Baltimore); 2017 Jun; 96(25):e7133. PubMed ID: 28640087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Lactic Acidosis Due to Acute Intoxication by Emtricitabine/Tenofovir Alafenamide.
    Chaparala S; Da Silva RC; Papadopoulos JP
    Cureus; 2021 Oct; 13(10):e19008. PubMed ID: 34824925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
    McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C
    N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    Triantos C; Kalafateli M; Aggeletopoulou I; Mandellou M; Assimakopoulos S; Tselekouni P; Taprantzi D; Tsiaoussis G; Vourli G; Anastassiou ED; Gogos C; Labropoulou-Karatza C; Thomopoulos K
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):998-1003. PubMed ID: 28746158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
    Lange CM; Bojunga J; Hofmann WP; Wunder K; Mihm U; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):2001-6. PubMed ID: 19937695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
    Fung J; Seto WK; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 Mar; 29(3):428-34. PubMed ID: 24372662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
    Sato K; Inoue J; Akahane T; Kobayashi T; Takai S; Nakamura T; Sato T; Kimura O; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A
    Tohoku J Exp Med; 2022 Nov; 258(4):277-285. PubMed ID: 36244758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B.
    Cohen SM; Levy RM; Jovanovich JF; Ahn J
    J Clin Gastroenterol; 2009; 43(10):1008-10. PubMed ID: 19461528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
    Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study.
    Han G; Zhou G; Sun T; Luo X; Xu J; Chen C; Xu W; Jiang S; Wang C
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10551-10558. PubMed ID: 36253882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature.
    Zheng J; Deng M; Qiu X; Chen Z; Li D; Deng X; Deng Q; Yu Z
    J Med Case Rep; 2017 Nov; 11(1):331. PubMed ID: 29179767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Buti M; Marcos-Fosch C; Esteban R
    Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
    Bernstein DE; Trinh HN; Schiff ER; Smith CI; Mospan AR; Zink RC; Fried MW; Lok AS
    Dig Dis Sci; 2022 Jun; 67(6):2637-2645. PubMed ID: 34059991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
    Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C
    J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic hepatitis B: virological and pharmacological aspects].
    Foucault T; Handala L; Paintaud G; Gaudy-Graffin C; Marlet J
    Virologie (Montrouge); 2022 May; 26(3):228-239. PubMed ID: 35792839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.